Abu Dhabi Biobank partners with BioTwin to bring AI ‘virtual human twin’ technology to the UAE

Abu Dhabi Biobank has signed a strategic partnership with Canadian health tech company BioTwin to deploy AI-powered virtual human twin technology across the emirate. The goal is to shift healthcare from treating illness to predicting and preventing it, starting with early cancer detection.

The deal was announced at the BIO International Convention 2026 in San Diego. Abu Dhabi Biobank is a joint initiative between the Department of Health Abu Dhabi (DoH) and M42, a global health company. BioTwin brings a longitudinal biomarker platform that combines home-based blood collection, multi-biomarker analysis, and AI modeling to build a continuously updated digital picture of a person's health.

Together, the two organizations plan to connect BioTwin's individual health profiles with Abu Dhabi Biobank's genomic, clinical, and biological data to generate earlier warning signals for disease, design prevention strategies, and deliver more personalized care at population scale.

How will it work?

BioTwin's platform works by collecting biological data over time, not just at a single point. Here's how the system is designed:

• Patients collect blood samples at home using dried blood spot kits, which are then analyzed for multiple biomarkers.
• AI models use that data to build a "virtual human twin," a digital representation of an individual's health trajectory.
• Over time, the platform tracks changes and generates longitudinal insights, spotting patterns that might indicate early disease or elevated risk.
• Abu Dhabi Biobank adds another layer by linking these profiles to genomic data, clinical records, and population-scale health information.

The first application will focus on multi-cancer screening. If that goes well, the partnership plans to expand into preventive health more broadly, including health optimization and personalized care programs.

Why does it matter?

Early detection saves lives. That's the simple reason this kind of partnership matters. Most cancers, and many chronic diseases, are far easier to treat when caught early, but current healthcare systems are largely built around responding to symptoms rather than anticipating them.

What makes this deal notable is the combination of assets involved:

• Abu Dhabi Biobank has access to high-quality biological materials, governed data infrastructure, and real-world population data at scale.
• BioTwin brings a consumer-friendly collection method and AI modeling that can track health changes over months and years.
• The UAE's regulatory environment is designed to support fast iteration and real-world implementation, which matters when you're trying to move from research to clinical deployment.

Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi, described the emirate's ambition plainly: "This model creates the foundation for predictive, preventive and personalised future of health, resulting in earlier intervention at population scale that builds a healthier community."

Louis-Philippe Noel, Founder and CEO of BioTwin, said the partnership is "a major step" in making early detection and personalized health optimization accessible through virtual twin technology.

The context

Abu Dhabi has been building its life sciences infrastructure for years. The city has invested heavily in genomics through the M42-backed Biobank, in clinical research capacity, and in regulatory frameworks designed to attract health tech companies looking to run real-world pilots at scale.

Globally, the virtual human twin concept is gaining serious traction. The idea, using continuously updated digital models of individual patients to guide clinical decisions, has moved from academic research into commercial health platforms over the past few years. Several companies are now racing to make the technology practical and affordable outside of hospital settings.

The home-based blood collection angle is also significant. One of the biggest barriers to longitudinal health monitoring is convenience. If people have to visit a clinic every few months for tests, most won't. Dried blood spot collection, done at home and mailed to a lab, removes that friction and makes sustained monitoring far more realistic for large populations.

Albarah El-Khani, Chief Operating Officer for Integrated Health Solutions at M42, summed up the opportunity: "Abu Dhabi Biobank provides not only access to high-quality biological materials, but also to data, governance and translational pathways." That combination, good data, clear governance, and a path to clinical deployment, is exactly what health tech companies need to move from concept to practice.